Ruggiero Antonio, Ferrara Pietro, Attinà Giorgio, Rizzo Daniela, Riccardi Riccardo
Division of Paediatric Oncology, Catholic University of Rome, Rome, Italy.
Institute of Paediatrics, Catholic University of Rome, Rome, Italy.
Br J Clin Pharmacol. 2017 Dec;83(12):2605-2614. doi: 10.1111/bcp.13388. Epub 2017 Sep 20.
The clinical use of antineoplastic drugs can be limited by different drug-induced toxicities. Of these, renal dysfunction may be one of the most troublesome in that it can be cumulative and in general is only partially reversible with the discontinuation of the treatment. Renal toxicity may be manifested as a reduction of the glomerular filtration rate, electrolyte imbalances, or acute renal failure. Careful assessment of renal function has to be performed taking into account that the impairment of renal function is initially silent and only later may be clinically dramatic. When clinically indicated, the reduction or, in cases of severe nephrotoxicity, the suspension of chemotherapy should be considered to avoid the progressive deterioration of the compromised glomerular and/or tubular function.
抗肿瘤药物的临床应用可能会受到不同药物诱导毒性的限制。其中,肾功能障碍可能是最棘手的问题之一,因为它具有累积性,而且一般来说,在停止治疗后仅部分可逆。肾毒性可能表现为肾小球滤过率降低、电解质失衡或急性肾衰竭。必须仔细评估肾功能,因为肾功能损害最初是隐匿的,只有在后期才可能在临床上表现明显。当有临床指征时,应考虑减少化疗剂量,或者在严重肾毒性的情况下暂停化疗,以避免受损的肾小球和/或肾小管功能的进行性恶化。